A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kefford, R F, Thomas, N P B, Corrie, P G, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, M, Mortimer, P, Watson, A J, Margison, G P, Middleton, M R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2009
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676549/
https://ncbi.nlm.nih.gov/pubmed/19367282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605016
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars